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CLEAVAGE SITE COMPENSATORY SUBSTITUTIONS PARTIALLY 
RESTORE FITNESS TO SIMIAN IMMUNODEFICIENCY VIRUS VARIANTS 
OSCAR B. ALCOREZA JR. 
ABSTRACT 
The human immunodeficiency virus is presently one of the most significant 
global health issues to date, with a disease burden that encumbers developing and 
developed nations alike. Although current antiretroviral therapy can help patients 
maintain undetectable levels of the virus throughout their bodies, once the treatment is 
ceased, the virus will rebound and disease progression continues. Thus, modalities to; 1- 
stop HIV transmission and spread, or 2- eradicate the virus once it is acquired are both 
urgently needed.   
In this project, we seek to evaluate and understand the impact of a candidate 
vaccine therapy that targets the HIV protease cleavage sites (PCS) on viral fitness. 
Vaccination with this modality in a monkey model induces mutations at virus regions that 
are intolerant to change, presumably affecting the “fitness” of viral strains recovered 
from vaccines.  Preliminary results of the study show that in the vaccine group (n=11), a 
disruption to one or more of the HIV protease cleavage sites results in improved 
maintenance of CD4+ T cells compared to unvaccinated controls (n=5). Furthermore, a 
correlation between the percentage of PCS mutations and reductions in viral load were 
seen. Our data indicate that the most common sites of mutation occur at two cleavage 
regions PCS2 and PCS12. We used site directed mutagenesis to introduce multiple PCS 
mutations into infectious clones of SIV. Our ongoing studies are evaluating the viral 
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fitness of the SIV mutants in a cell lines and PBMC using competitive viral fitness 
assays. The data from these studies will help inform in the areas of vaccine and therapy 
development for HIV-1. 
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INTRODUCTION 
HIV and AIDS: 
 In 1984 several laboratories independently isolated viruses thought to be the 
etiologic agent responsible for acquired immune deficiency syndrome (AIDS) (Levy, Jay, 
2007). These virus isolates were determined to be the same agent and was ultimately 
given the name human immunodeficiency virus (HIV). Since the discovery that HIV was 
responsible for AIDS, two species of the virus have been isolated, HIV-1 and HIV-2. 
HIV-1 is the most prominent and infectious strain of HIV (Levy, Jay, 2007) . HIV 
exhibits broad diversity with four HIV-1 sub-groups and eight HIV-2 groups having been 
characterized. HIV-1 group M (Major) is responsible for the current AIDS epidemic and 
nine clades have also been identified. HIV infection has three general clinical stages that 
include acute infection, clinical latency (lasting an average of 3-10 years) and AIDS 
(characterized by a CD4+ cell count of 200cells/mm3 or lower). Individuals left untreated 
with AIDS survive an average of 3 years (AIDS.gov).  
 Transmission of HIV-1 occurs principally through the exchange of genital 
secretions, blood or breast milk that contain cell-associated and cell-free virus. Sexual 
transmission is the most common route of transmission, yet is the least efficient with 1 
out of 1000 sexual encounters resulting in a transmission event (Levy, Jay, 2007). Sexual 
transmission can be increased by several factors including circumcision status, presence 
of inflammation or ulcers in genital mucosa. Although, transmission from mother-to-
child via breast feeding and the sharing of needles among intravenous drug users are 
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higher risk transmission routes, they have low overall incidence rates and contribute 
substantially less to HIV prevalence (Sagar, 2014).  
 In 2011, there were an estimated 34.2 million persons living with HIV, of which 
2.5 million were new infections and 1.7 million died (Lou, Chen, Yu, Li, & Ye, 2014). 
Despite these sobering statistics, there has been significant progress in HIV treatment in 
the past few decades. The advent of antiretroviral therapy (ART) has been the greatest 
success in HIV/AIDS medicine to date (Richman et al., 2009). The life expectancy of a 
person living in the US with HIV starting ART at 20 years old has increased by 15 years 
from 2000 to 2006 (Samji et al., 2013).  
 In the US, HIV-1 infection is now considered a chronic, manageable disease. 
Unfortunately the majority of people living with HIV-1 live in low-income countries 
where life-long ART is not readily available, nor a feasible treatment option (Dorling, 
Shaw, & Davey Smith, 2006). These facts raise an impetus to go beyond managing life- 
long HIV/AIDS, which comes at a health and financial cost, to developing an efficacious 
prophylactic vaccine and potentially a cure for already-infected patients.  
 
HIV Genetic Organization- 
 HIV belongs to the genus Lentivirus within the family Retroviridae. The HIV 
virion is composed of a conical protein capsid housing two copies of the positive single-
stranded RNA genome and the enzymes reverse transcriptase, integrase and protease 
(Kartikeyan, Bharmal, Tiwari, & Bisen, 2007). Surrounding the viral capsid is a two 
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layered envelope that is derived from the host cell membrane as progeny virus leave the 
host in a process termed “virus budding” (Sundquist & Krausslich, 2012). The outermost 
viral envelope contains glycoprotein subunits that project out of the envelope itself, 
forming a dense “glycan or sugar shield” that aids immune escape and evasion by 
blocking host antibody recognition of “glycan masked” envelope proteins. Glycoprotein 
120 (gp120) is one such projection that is connected to the virion via a transmembrane 
protein, termed glycoprotein 41 (gp41). Gp120 is responsible for binding to target cells 
which express the CD4 receptor (Melikyan, 2014).   
 The HIV-1 genome can be grouped by genes encoding non-structural genes (tat, 
rev, nef, vpr, vif and vpu), which regulate the replication cycle and differentiate HIV from 
other retroviruses, and structural proteins (gag, env and pol), which are common to all 
retroviruses (Kartikeyan et al., 2007). The tat gene expresses Tat (trans-activating) 
protein that activates the transcription of all viral genes. The rev gene produces Rev 
(regulatory of virus) protein activates expression of both structural and enzymatic genes. 
The nef gene produces Nef (negative factor) protein that is believed to regulate viral 
latency. The vif gene expresses Vif (viral infectivity factor) protein that assists the viral 
budding process. The vpr gene expresses Vpr protein and has been shown to stimulate the 
promoter region of HIV. The vpu gene, present only in HIV-1, encodes for various small 
proteins whose functions remain unknown, but is believed to play a role in mediating the 
release of budding new progeny virus (Dubé, Bego, Paquay, & Cohen, 2010).  
 The gag gene, is the major HIV structural component and encodes the (3) virion 
core and capsid proteins (CA, NC and p2). The env gene encodes the envelope 
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glycoproteins gp120, responsible for CD4 binding, and gp41, which is involved in the 
fusion of viral and host cell membranes (Sundquist & Krausslich, 2012). The pol gene 
encodes the enzymes reverse transcriptase, integrase and protease. Reverse transcriptase 
converts the single stranded RNA genome into a DNA duplex once inside the host cell. 
Integrase is responsible for integrating the DNA duplex into the host cell genome as 
proviral DNA. Protease is the enzyme that cleaves all the precursor polypeptides into 
functional proteins and is essential for the formation of infectious virus (Pokorná, 
Machala, Řezáčová, & Konvalinka, 2009). 
 
HIV Protease- 
The HIV-1 Protease is biologically active as a symmetrical dimer and is the target 
of 9 Protease Inhibitors (Saquinavir, Indinavir, Ritonavir, Nelfinavir, Lopinavir, 
Atazanavir, Fosamprinavir, Tipranavir and Darunavir) used in ART (Warnke, Barreto, & 
Temesgen, 2007). The protease enzyme is active during the later phase in the HIV 
replication cycle when precursor polypeptides transcribed from proviral DNA are cut at 
12 conserved protease cleavage sites (PCS), thus activating the individual 
proteins/enzymes into their functional forms (de Oliveira et al., 2003; Kartikeyan et al., 
2007).  
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HIV-1 Reverse Transcriptase- 
The HIV Reverse Transcriptase (RT) is a critical component of the virus and 
unique in it’s ability to reverse transcribe RNA to DNA.  The recognition of this ability 
resulted in the award of a Nobel Prize (Temins, Baltimore and Dulbecco). HIV-1 RT 
lacks a proofreading mechanism which results in 3 x 10^-5 mutations per base pair per 
cycle. This high mutation rate coupled with a fast replication cycle of 10^10 viral 
particles per day enables HIV to exist in a host as quasi-species with subtle mutations that 
persist in response/adaptation to host immune pressure (Coffin, 1995; Tebit, Nankya, 
Arts, & Gao, 2007). A 1995 study by Ho et al., revealed that the half-life of HIV in vivo 
was around 2 days, representing an extremely rapid turnover rate (Ho et al., 1995). These 
properties enable HIV to respond to the host immune pressure, and any potential therapy, 
through the natural selection of the “most-fit” virus in which any beneficial mutation is 
rapidly selected for and maintained. The HIV-1 RT was initially the primary target for 
antiretroviral therapy and an entire class of molecules termed “RT inhibitors” (including 
3TC and AZT, PMPA and FTC) underscore the level of work in this area.   
 
The full HIV genome as well as the mature HIV virion are shown in Figure 1.  
	  6 
 
Figure 1. (A) Illustration of the full HIV genome structure including the long-terminal 
repeats (LTR) (B) Illustration of the HIV virion including the major membrane, capsid 
and matrix proteins as well as key enzymes. Figure adapted from Shum et al., 2013. 
Viral Evolution in Response to Host Immunity- 
 HIV preferentially infects CD4+ T-cells, using the CD4 receptor and CXCR4, 
CCR5 co-receptors to gain cellular entry (Mogensen, Melchjorsen, Larsen, & Paludan, 
2010). There is also evidence that HIV-1 trans infection of CD4+ T-cells by professional 
antigen presenting cells (APCs), such as macrophages, dendritic cells and B-
lymphocytes, could be a major contributor to the precipitous decline of CD4+ T-cells 
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seen as the infection progresses (Rinaldo, 2013).  As CD4+ T-cells play an important role 
in adaptive immunity, there is a strong negative correlation between declining CD4+ T-
cell counts and progression to AIDS (Paiardini & Müller-Trutwin, 2013). CD4+ Central 
Memory T-cells represent the largest infected reservoir of CD4+ T-cells due to their role 
in maintaining normal CD4+ T-cell levels in the body, termed homeostasis (Paiardini & 
Müller-Trutwin, 2013).  
 Studies examining virus from individuals with acute HIV infection provided 
insight into the complex interactions between HIV and host immunity. In these patients 
neutralizing antibodies (Nab) were detected as early as 52 days after confirmation of 
infection. However, these Nab became ineffective after complete replacement of Nab 
sensitive virus with virus that contained mutations in HIV Env which conferred resistance 
to the Nab (Wei et al., 2003). This study also proposed the idea that HIV possesses a 
“glycan shield” capable of high diversity to prevent Nab binding without affecting 
receptor binding. In addition to neutralization escape, HIV is capable of acquiring drug 
resistance through the maintenance of mutations rendering antiretroviral drugs ineffective 
(Tang & Shafer, 2012). However, researchers have demonstrated that drug resistance 
mutations almost invariably come at a fitness cost to the virus. Thus, the drug-resistant 
virus must sacrifice replicative fitness to persist in the presence of the drug. 
 During acute infection, the initial decline in virus is believed to occur due to 
increases in CD8+ T-cells, or cytotoxic T-lymphocytes (CTL), which are critical for viral 
control and help in establishing the viral load set-point (Koup et al., 1994; McMichael, 
Borrow, Tomaras, Goonetilleke, & Haynes, 2010). This viral load set point represents the 
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stable production of virus in HIV+ individuals as the balance between HIV replication 
and host immune system pressure is reached.  
 Studies analyzing the immune systems of individuals capable of controlling HIV 
infection without ART, termed elite controllers (EC) or long-term non-progressors 
(LTNP), have found that there is a strong correlation between certain major 
histocompatibility complex (MHC) alleles and increased HIV-1 control (Zaunders & van 
Bockel, 2013). Similarly to escape from antibodies and antiretroviral drugs, HIV-1 is able 
to produce and maintain CTL escape mutations. Investigation into CTL escape mutations 
revealed that a small portion of these mutations come at a high fitness cost to the virus 
and often require compensating mutations at other sites on the virus genome, which 
mitigate the fitness cost of CTL escape (Goulder & Watkins, 2004). This “fitness cost” 
has been demonstrated through ex vivo studies of HIV with CTL escape mutations 
against HLA-B57 infecting a population of cells without HLA-B57. For example, the loss 
of immune pressure towards the maintenance of the B57 escape mutation caused rapid 
reversion of mutant HIV, with CTL-escape mutations, back to the more pathogenic wild-
type sequences (Leslie et al., 2004).  
Ongoing Hurdles in HIV-1 Vaccine Development- 
 Despite over three decades of HIV research there has been only four HIV-1 
vaccine candidates that have managed to reach clinical efficacy trials.  
 The first HIV vaccine candidate to reach clinical efficacy trials was one that used 
recombinant HIV-1 envelope glycoprotein subunit (rgp120) to attempt to induce a potent 
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immune response capable of eliciting broad, potent neutralizing antibodies (Group, 
2005). The results of this study concluded that the vaccine provided no overall protective 
effects. The second vaccine candidate was an adenovirus serotype 5 (Ad5) vector vaccine 
which expressed viral Gag, Pol and Nef proteins. The primary objective of this trial was 
to reduce HIV-1 acquisition rates and viral set point in vaccine recipients primarily 
through cell-mediated immunity. Although an increase in CTL response was observed, 
via IFN-γ ELISPOT, the results of this study also showed no protective effects and may 
have increased the risk of infection, as the vaccine group had a higher incidence of 
infection than the control group (Buchbinder et al., 2008). The third vaccine candidate 
was a prime-boost vaccine regimen involving four priming injections of recombinant 
canarypox vaccine vector, followed by two booster injections of the rgp120 vaccine. This 
candidate vaccine was able to provide a modest efficacy of prevention of HIV incidence 
of 31.2%. However, the vaccine failed to modify the degree of viremia or CD4+ T-cell 
counts of those who became infected (Rerks-Ngarm et al., 2009). Additionally, the 
protective effect waned rapidly following treatment. The last vaccine candidate to reach 
clinical efficacy trials was a DNA prime-recombinant Ad5 boost regimen which was 
stopped early due to lack of efficacy (Hammer et al., 2013)(Barouch, 2013).  
Barriers to a Cure for HIV- 
 To date, there is but a single documented case of a “sterilizing” or absolute HIV-1 
cure, in the well-described “Berlin Patient” (Hütter et al., 2009). This is likely due to the 
fact that HIV exhibits numerous characteristics that have defied the development of a 
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curative treatment. These include its preferential infection of immune cells, rapid 
turnover, high mutation rate, and viral latency.    
Despite ART’s ability to control HIV infection long-term with minimal clinical 
symptoms, a persistent, replication competent HIV reservoir has been shown to exist in 
patients on ART (T. W. Chun et al., 1997; Finzi et al., 1999). Finzi et al., attempted to 
characterize the decay kinetics of the latently infected resting CD4+ T-cell reservoir, on 
potent ART, and estimated that eradication of the latent reservoir could take as long as 60 
years (Finzi et al., 1999; Ho et al., 1995) 
 This replication competent latent reservoir represents the next major obstacle in 
achieving a sterilizing cure for HIV. Chun et al., demonstrated that in a patient who had 
been on ART for over a decade, had undetectable plasma proviral DNA (from latently 
infected cells) and undetectable proviral DNA in the gut associated lymphoid tissue 
(GALT), nevertheless had a rebound of plasma viremia 50 days after discontinuation of 
ART (T.-W. Chun et al., 2010). A study by Whitney et al., revealed that the use of ART 
for 24 weeks starting as early as three days post infection in rhesus monkeys was not 
sufficient in preventing the formation of a latent reservoir (Whitney et al., 2014). These 
studies demonstrate that a successful sterilizing therapy must be capable of eliminating 
all traces of replication competent HIV, given that a small, undetectable reservoir, as 
small as a single infected cell, is capable of reigniting the infection (Ananworanich & 
Robb, 2014; Persaud et al., 2013). 
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Elite Controllers- Insights into Natural Resistance to HIV- 
 Generally, the concept behind HIV-1 immunotherapy (a vaccine or other 
therapeutic) is a therapy that is able to diminish the pathogenicity of HIV-1 and/or 
strengthen a patient’s immune system to the point where it is able to keep the virus in 
check (Blankson, Siliciano, & Siliciano, 2014). Many unique clinical cohorts exist that 
can inform the rationale design of vaccines or similar immune therapies for HIV-1. This 
concept for a “functional cure” is based on the study of ECs and LTNPs, who are 
individuals infected with or exposed to HIV but do not progress to AIDS due to an 
immune system capable of effectively controlling the infection. Through the study of 
ECs, researchers have learned how the body can naturally control infection and scientists 
can use these insights in the development of more effective treatments.  
 Human leukocyte antigens (HLA) are the human equivalent of the MHC gene 
family that is involved in immune system pathogen recognition. These host proteins play 
an important role in immune surveillance through the binding and presentation of self and 
foreign proteins to T-cells. There is an enormous diversity of HLA alleles that contribute 
to variable levels of peptide binding and recognition in the human population. Study of 
ECs has revealed a high percentage of specific HLA alleles that are thought to contribute 
to better viremic control. Specifically, HLA-B*2705, HLA-B*5701 and HLA-B*5703 
alleles have been extensively studied due to their presence in EC (Zaunders & van 
Bockel, 2013) (Migueles et al., 2000). 
Another unique set of individuals is the Pumwani Commercial Sex Worker 
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Cohort study involved the observation of 424 initially seronegative sex workers in 
Nairobi, Kenya from 1985-1994. The results of this study demonstrated that 43 women in 
this group remained seronegative throughout 3+ years of follow up. Despite an estimated 
500 unprotected exposures to HIV-1, a small group of women appeared to have a natural 
immunity to HIV-1 (Fowke et al., 1996). One study investigating the CTL response in 
this cohort revealed that 40% of the HIV seronegative individuals had an IFN-gamma 
response, which corresponds to cytotoxic function, five times less than the HIV+ group. 
The seronegative group also had a 10-fold lower HIV-envelope specific CD8+ T-cell 
response, responding to only a single HIV peptide, compared to the HIV+ group which 
responded to an average of 5.5 peptides (Alimonti et al., 2006). Comparison of HLA 
allele A*01:01, which is represented in the Pumwani seronegative group, and HLA allele 
B*07:02, which is associated with susceptibility for HIV-1 infection, revealed that the 
B*07:02 allele bound ten times more HIV-1 Gag epitopes than the protective A*01:01 
allele (M. Luo et al., 2012).  
These observations reveal the potential requirement of an effective curative 
treatment to elicit a highly specific, narrow immune response, in contrast to the strong, 
broad immune response elicited by some of the previously described experimental 
vaccines.   
In addition to natural immunity there have been cases of non-progression due to 
infection by attenuated viruses. A study examining the HIV-1 nef gene sequences of five 
LTNP revealed one patient who generated only defective forms of nef in 34 blood 
samples obtained in a 10 year period (Kirchhoff, Greenough, Brettler, Sullivan, & 
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Desrosiers, 1995). The disease progression of this patient was similar to the progression 
of rhesus monkeys inoculated with a SIVmac239 clone containing a defective nef gene. 
This case demonstrates the potential of a normal individual, infected predominantly by an 
attenuated form of HIV, being capable of controlling viremia and disease progression. 
Importance of Viral Fitness in Therapy- 
 Viral fitness is a multifaceted term that describes HIV’s replicative ability within 
a given environment. Due to the unique nature of HIV infection and its replicative 
characteristics, descriptions of fitness should be approached cautiously. However, given 
the observations that escape mutations often develop at the expense of replicative fitness, 
it may be possible to develop a therapeutics, that generate selective pressures strong 
enough to force HIV to mutate into an attenuated variant that an individual’s immune 
system can then control. Studies have shown that HIV-positive individuals who maintain 
viral loads lower than 1,700 copies per ml were not able to transmit HIV to their partners 
(Goulder & Watkins, 2004). This highlights the complexity of describing HIV-1 fitness 
vis-à-vis virus transmission, control of viremia and disease progression (see Figure 2). 
Towards this end it is necessary to have an accurate mechanism to measure 
relative fitness. A study by Peyerl et al., assessed the fitness loss of a rare SHIV CTL 
escape mutation (T47I) at a highly conserved Gag epitope and an associated 
compensatory mutation (I71V) (Peyerl et al., 2003). The T47I mutation alone resulted in 
a substantial decrease in gag p27 expression however a mutant clone with both T47I and 
I71V mutations “reverted” and expressed p27 at near wild-type levels. Another 
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determinant of viral fitness examined in this study included viral infectivity and 
replication. To measure infectivity, the env gene of mutated SHIV clones were replaced 
with the E. Coli CAT gene and pseudotyped with an HIV-1 envelope glycoprotein to 
allow entry into rhesus monkey PBMCs. Once again, the mutant virus containing only 
the T47I mutation expressed only background levels of CAT expression while the variant 
with both T47I and I71V mutations had wild-type levels of CAT expression. While these 
methods provide a limited way to compare viral fitness they do not represent the highly 
complex in vivo competition that exist between HIV quasi-species.  
Quiñones-Mateu et al., developed a dual infection/competition assay that is able 
to accurately measure relative virus production and ex vivo fitness. This study used four 
control HIV-1 strains (two non-syncytium inducing/CCR5 tropic strains and two 
syncytium inducing/CXCR4) to evaluate the relative fitness of HIV-1 isolates from a 
Belgian cohort study. The results revealed that HIV-1 isolates from LTNPs were 
outcompeted by the control strains and were significantly less fit than HIV-1 isolates 
from patients with rapid progression to AIDS (Quiñones-Mateu et al., 2000). The results 
also revealed a direct correlation between ex vivo viral fitness and viral load. These 
results demonstrate that LTNP, possibly due to more effective CTL function, may be 
capable of attenuating HIV-1 infection to halt the progression to AIDS.  
This type of reliable, ex vivo competition assay is critical for the further study and 
understanding of the contradictions that have been observed concerning CTL-mediated 
immune pressure and virus escape from immune control. For example, one study 
mentioned showed that fitness reducing CTL-escape mutants are capable of returning to 
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wild-type fitness through compensatory mutations (Peyerl et al., 2003), while another 
study demonstrates that LTNP, presumably through more effective CTL function, are 
capable of applying enough immune pressure to force the progression of less-fit HIV 
(Quiñones-Mateu et al., 2000). In order to advance the intelligent design of immune-
based therapeutics, perhaps imitating the effective immune responses of natural LTNP 
and EC, it is vital to include and analyze comparative fitness of the dominant HIV-1 
quasispecies during experimental treatments. 
 
Background of Current Investigation- 
 The Pumwani Sexworker Cohort study revealed the existence of the protective 
HLA A*01:01 gag epitope allele, which corresponds to a 9-mer peptide covering the 
HIV-1 protein cleavage site 1, (termed PCS 1). A recent study (Ma Luo et al., 2013) of 
immunogenicity and world population coverage of a vaccine targeting all 12 HIV-1 
protease cleavage sites or “PCS” revealed that these sequences are immunogenic and 
many HLA class I alleles have target epitopes at multiple PCS.  
 Since the HIV-1 12 PCS are highly conserved (in order to maintain viral 
replication), we hypothesize that any deviation from the original sequence, due to 
immune-mediated immune pressure, will impact viral fitness. Knowing that the 
protective effect that the HLA A*01:01 CTL response confers, an experimental vaccine 
targeting the 12 highly conserved PCS on SIV was developed and tested in a monkey 
model of HIV-1 acquisition. Using 17 Cynomolgus macaques (Macaca fascicularis) as 
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our model for HIV, we tested the effects of a vaccine consisting of a cocktail of 20-mer 
peptides overlapping the 12 PCS.  After vaccination, the animals were experimentally 
infected with a close analog of HIV- its simian counterpart, SIV. 
 Analysis of SIV sequences from all monkeys during the periods when they 
experienced high (ranging from weeks 2-4 post-infection) and low (ranging from weeks 
6-17 post-infection) viral loads led to the selection of five mutations that dominated the 
virus population and persisted throughout the study in the majority of the subjects. Three 
of these mutations were located on PCS2 and two were located on PCS12. 
 The purpose of this thesis work is to examine the fitness of mutant clones of 
SIVmac239 containing the selected predominant mutations from Cynomolgus macaques 
that received an experimental vaccine consisting of a modified vesicular stomatitis virus 
(VSV) vector system expressing peptides overlapping 12 highly conserved SIV protease 
cleavage sites. We hypothesize that the mutant SIVmac239 clones will exhibit an altered 
fitness compared to a wild-type SIVmac239, unexposed to selective pressures. The long-
term objective of this work is to further characterize deficits in viral fitness as a result of 
PCS-based vaccine strategies and response to immune pressure. This data will inform the 
development of vaccine concepts capable of eliciting effective immune control and 
preventing further transmission.	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METHODS  
 
 Animals, SIV Challenge and Vaccination Protocol 
This study enrolled and monitored adult Cynomolgus macaques (Macaca 
fascicularis). All animals were genotyped for their MHC haplotypes using PCR and 
MHC-amplicon sequencing. The monkeys were housed under biosafety level-2+ 
conditions, and routinely monitored by physical exam and T cell subset analysis before 
and after SIV infection.  
Specimen Collection and Processing   
Peripheral blood was collected weekly. PBMC from collected blood were 
separated on Ficoll-Hypaque cushions following standard protocols, while blood plasma 
was immediately frozen and maintained at –80ºC until use. All PBMC cultures were first 
purified by CD8-depletion using a commercial MACS magnetic bead depletion assay 
(Miltenyibiotec inc.) and then cryopreserved and frozen at -180ºC for later use. After 
thawing, all PBMC were stimulated for 48hrs with Concanavalin A, prior to use in 
experiments. PBMCs were maintained in lymphocyte medium (RPMI 1640 with 10% 
FBS and 40 U/ml IL-2).  
Viral RNA Extraction and qRT-PCR Detection   
Viral RNA was routinely isolated from 140 µL of blood plasma using the QIAamp Viral 
RNA Mini Kit (Qiagen) following the manufacturer’s protocol. RNA recovered from 
spin columns was eluted to a final volume of 60 µL.     
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cDNA Synthesis   
A 10µL volume of extracted RNA was reverse transcribed to single-stranded 
cDNA following the manufacturer’s instructions in the Superscript III protocol 
(Invitrogen).  RNA, deoxynucleotides (0.5 mM each), and 0.24 µM primer OR9608 (5’ – 
CTCATCTGATACATTTACGGGG – 3’) were incubated for 5 minutes at 65ºC.  The 
sample was chilled on ice for 1 minute, followed by a brief centrifugation.  First strand 
cDNA synthesis was completed by adding 10 µL of 5x reaction buffer, 2.5 µL each of 
0.1 M DTT, RNase Out, and Superscript III RT.  The mixture was then incubated for 60 
minutes at 50ºC, 60 minutes at 55ºC and 15 minutes at 70ºC.  Finally, 5 units of RNase H 
were added and the mixture was incubated for 20 minutes at 37ºC. 
QPCR assay 
The SIV RNA standard was transcribed from the pSP72 vector containing the first 
731 bp of the SIVmac239-Gag gene using the Megascript T7 kit (Ambion Inc., Austin, 
TX).  RNA was isolated by phenol-chloroform purification followed by ethanol 
precipitation. All purified RNA preparations were quantified by optical density.  RNA 
quality was determined using Agilent bioanalyzer RNA chip (Agilent Santa, Clara CA).  
QRT-PCR was conducted in a 2-step process. First, RNA was reverse transcribed 
in parallel with a SIV-gag RNA standard using the gene-specific primer sGag-R 
5’CACTAGGTGTCTCTGCACTATCTGTTTTG-3’ under the following conditions:  the 
50 µL reactions contained 1X buffer (250 mM Tris-HCL pH 8.3, 375 mM KCl, 15 mM 
MgCl2), 0.25 µM primer, 0.5 mM dNTPs (Roche), 5 mM dTT, 500 U Superscript III RT 
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(Invitrogen, Carlsbad, CA), 100 U RnaseOUT (Invitrogen, Carlsbad, CA), and 10 µL of 
sample.  RT conditions consisted of 1 hour at 50˚C, 1 hour at 55˚C and 15 minutes at 
70˚C.  All samples were then treated with RNAse H (Stratagene, Cedar Creek, TX) for 20 
minutes at 37˚C.  All real-time PCR reactions used EZ RT PCR Core Reagents (Applied 
Biosystems, Foster City, CA) following the manufacturer’s suggested instructions under 
the following conditions: the 50µL reactions contained 1X buffer (250 mM Bicine, 575 
mM potassium acetate, 0.05 mM EDTA, 300 nM Passive Reference 1, 40% (w/v) 
glycerol, pH 8.2, .3 mM each of dATP, dCTP, dGTP, .6 mM dUTP, 3 mM Mn (OAc)2, 
.5 U uracil N-glycosylase, 5 U rTth DNA Polymerase, .4 uM of each primer, and 10µL of 
sample template.  PCR reagents were assembled at room temperature and spun briefly to 
eliminate air bubbles.  Following 2 minutes at 50˚C, the polymerase was activated for 10 
minutes at 95˚C, and then cycling proceeded at 15 seconds at 95˚C and 1 minute at 60˚C 
for fifty cycles. Primer sequences were adapted from those described by Cline et al 
(Nichole Cline, Bess, Piatak, & Lifson, 2005), forward primer s-Gag-F: 5’-
GTCTGCGTCATCTGGTGCATTC-3’, reverse primer s-Gag-R: 5’-
CACTAGGTGTCTCTGCACTATCTGTTTTG-3’, and the probe s-Gag-P: 5’-
CTTCCTCAGTGTGTTTCACTTTCTCTTCTGCG-3’, linked to Fam and BHQ 
(Invitrogen, Carlsbad, CA). All reactions were carried out on a 7300 ABI Real-Time PCR 
system (Applied Biosystems) in triplicate according to the manufacturer’s protocols. 
Construction of PCS mutant SIV clones  
The first step in the construction of the mutated SIV-PCS12- m-tracking vector, 
SIV-PCS12- m, involved subcloning of the region located between restriction sites SphI 
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(position 6701) and XhoI (position 10535) from the full-length infectious clone of 
SIVmac239, derived from a biological isolate of SIVmac251 as described by Whitney et 
al, into pSP73 (Promega). The resulting plasmid was subjected to site-directed 
mutagenesis in order to insert 2 nonsynonymous mutations into the PCS12 region using 
the Stratagene Quickchange II kit, as specified by the manufacturer. The mutagenized 
SphI-XhoI fragment was then inserted into the parental clone to produce the PCS-Mutant 
clone (PCS12-M). Infectious virus stocks were prepared by transient transfection of 293T 
cells with SIVmac239 wild type or PCS12-M plasmids using Lipofectamine 2000 
(Invitrogen, Carlsbad, CA) according to the manufacturer's instructions. 
Virus stocks 
Viruses used in the fitness studies are biological isolates and chimeric virus 
derived from the vaccine and control arms of a primate-based HIV-candidate vaccine 
study (Letvin et al., 2006). Stocks of each isolates were prepared and all infectious stocks 
were stored in aliquots at -80 °C. The titers (50% tissue culture infectious dose 
(TCID50)) of all stocks were determined in PBMC culture by standard methods and data 
was analyzed using the method described by Spearman and Karber. 
Growth-competition assays 
Growth-competition assays were performed in 12-well plates seeded with 2e 106 
PHA-activated rhesus PBMCs in 2 ml total volume. The two viruses under evaluation 
were added to the target cells at individual multiplicities of infection (MOI) of 0.001 or 
0.005, which are generally accepted to be low enough to prevent recombination. To limit 
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the natural variability of PBMC replication assays, each data point was derived from 
duplicate cultures on the same plate and all experiments were performed twice. The 
competition cultures described were maintained for 14 days. Supernatants were taken at 
day 3, 5, 7, 9 and 12. PBMC were harvested from these supernatants, washed twice with 
phosphate-buffered saline (PBS), and pelleted for DNA extraction using the QIAamp 
DNA Blood Mini Kit, following the manufacturer's instructions. Virus production in 
culture fluids was monitored using RT-PCR and SIV p27 antigen capture assay (Coulter 
Immunotech Inc., Westbrook, ME, U.S.A.). 
Single Genome Amplification of SIV Envelope   
To ensure that positive amplifications were a result of a single cDNA, viral cDNA 
was diluted in 96-well plates to yield fewer than 30% wells positive for amplification 
(Palmer et al., 2005).  First-round PCR was carried out in a reaction mixture containing: 
1x buffer (Platinum Taq HF Kit, Invitrogen), 0.2 mM dNTP mix, 2mM Mg2SO4, 0.2 µM 
primer OF6207 (5’ – GGGTAGTGGAGGTTCTGGAAG – 3’), 0.2 µM primer OR9608 
(5’ – CTCATCTGATACATTTACGGGG – 3’), 0.025 units of Platinum Taq High 
Fidelity polymerase into a total volume of 20 µL.  PCR mixtures were then loaded into 
MicroAmp Optical 96-Well Reaction Plates (Applied Biosciences). PCR conditions were 
programmed using the following parameters: 5 minutes at 94ºC, 35 cycles of 15 seconds 
at 94ºC, 30 seconds at 52ºC, 4 minutes and 15 seconds at 68ºC, followed by a final 
extension time of 10 minutes at 68ºC. For the second-round PCR, 2 µL of first-round 
PCR product was mixed with 1x buffer (Platinum Taq HF Kit, Invitrogen), 0.2 mM 
dNTP mix, 2mM Mg2SO4, 0.3 µM primer IF6428 (5’ – 
	  22 
CGTGCTATAACACATGCTATTG – 3’), 0.3 µM primer IR9351 (5’ – 
CCCTACCAAGTCATCATCTTC – 3’), 0.025 units of Platinum Taq High Fidelity 
polymerase into a total volume of 20 µL.  Second round PCR conditions were 
programmed using the following parameters: 5 minutes at 94ºC, 45 cycles of 15 seconds 
at 94ºC, 30 seconds at 51ºC, 3 minutes and 30 seconds at 68ºC, followed by a final 
extension time of 10 minutes at 68ºC.  Amplicons from cDNA dilutions resulting in less 
than 30% positive reactions were sequenced at the Dana-Farber/Harvard Cancer Center 
DNA Resource Core.  Eight sequencing primers spanning the length of the SIV envelope 
were used for complete envelope sequencing. For each monkey, between 15-30 SIV 
envelope sequences were analyzed per time point.  
SIV Envelope Sequence Analysis   
 Raw sequencing data was analyzed using the GeneCodes Sequencher 4.8 DNA 
sequencing software.  Using Sequencher’s assembly algorithm groups of primer sequence 
fragments were assembled into overlapping contigs. Chromatograms of assembled 
contigs were manually corrected for each individual ambiguous base.   
Alignments and Phylogenetic Analysis 
After editing contig consensus sequences they were then exported for translation 
by the Los Alamos National Laboratory (LANL) HIV sequence database translate tool 
(http://www.hiv.lanl.gov) for further bioinformatic analysis.  Nucleotide and translated 
contig consensus sequences were aligned with the online database EBI Tools ClustalW 
(Larkin et al., 2007) under default conditions.  Nucleotide alignments were manually 
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aligned, when necessary, with the BioEdit Sequence Alignment Editor program in 
preparation for phylogenetic analysis. 
 Edited sequences were also sent to Dr. Bette Korber of the Los Alamos National 
Laboratory for phylogenetic analysis, a brief methodology is described below. All 
phylogenetic analysis of nucleotide sequences was performed using the MEGA 4 
evolutionary analysis software package.  Evolutionary trees were inferred using the 
maximum parsimony and neighbor-joining methods.  The bootstrap consensus trees were 
inferred from 500 replicates and were taken to represent the evolutionary history of all 
taxa analyzed.  Maximum parsimony trees were obtained using the Close-Neighbor-
Interchange method in which the initial trees were obtained with the random addition of 
sequences (10 replicates). All positions containing gaps and missing data were eliminated 
from the datasets. 
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RESULTS 
Vaccine targeting protease cleavage sites elicited control of viremia. 
 As classical vaccine approaches to elicit either T cell or antibody responses 
against HIV-1 has failed so far or produced a modest effect, new approaches are needed. 
The immunogenicity of the sequences around the protease cleavage sites (PCS) and the 
population coverage for a vaccine targeting HIV-1 PCS has been investigated (Ma Luo et 
al., 2013). In the pilot study, sequences around PCS were assessed as targets for the 
development of a new vaccine strategy using Philippine Cynomolgus macaques and 
SIVmac239 as an experimental model. The vaccine regimen included immunogens that 
are cocktails of 20mer peptides overlapping the 12-protease cleavage sites (PCS).  
 Both plasma SIV RNA levels and CD4+ T cell counts were monitored in this 
cohort of cynomolgus monkeys through 20 weeks after SIVmac239 challenge. No 
significant changes in viral load were observed within the vaccine or control group 
mostly due to higher dose of SIVmac239 used to infect the vaccine group (Figure 2A). 
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Figure 2. The kinetics of plasma SIV RNA and total CD4+ T cell counts following 
SIVmac239 infection. (A) Plasma virus RNA levels were assessed in cynomolgus 
monkeys between wks 1 to 20 after challenging with SIVmac239. Log10 SIV RNA 
copies/mL for each monkey in both the vaccine (red) and control (blue) groups is shown. 
Median viral loads in both the vaccine (black solid) and control (black dashed) groups are 
also shown. (B) Changes in CD4+ T cell counts for each monkey in both the vaccine 
(red) and control (blue) groups over time were plotted. 
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 However, the vaccine group maintained CD4+ T cell counts better than the control 
animals, despite having increased levels of virus challenge (Figure 2B, Table 1). 
 
 Vaccine (n=11) Control (n=5) 
Weeks after 
infection 
# of animals with 
CD4 decline (%) 
# of animals with 
CD4 maintain (%) 
# of animals with 
CD4 decline (%) 
# of animals with 
CD4 maintain (%) 
MID11 5 (45) 6 (56) 3 (60) 2 (40) 
MID13 4 (36) 7 (64) 4 (80) 1 (20) 
MID14 7 (64) 4 (36) 4 (80) 1 (20) 
Endpoint 5 (45) 6 (56) 4 (80) 1 (20) 
 
Table 1. Change in total CD4+ T cell counts in cynomolgus macaques following 
infection. Monkeys in the cohort are shown in 2 groups, one of animals that showed 
decline in total CD4+ T cell counts and the other of animals that maintain CD4+ T cells. 
 
 This vaccine modality can generate antibody and T cell responses in macaques. 
Indeed, the antibody response to the peptides overlapping the PCS has been correlated 
with a reduction in viral load during the acute phase of SIV infection, while long-term 
durable control during the chronic stages, i.e. set-point is less pronounced (Figure 3A, 
B).  Vaccine-elicited control of viral load was maintained over the course of 20 wks post-
challenge as shown by significant associations between the vaccine elicited antibody 
response and an area-under-the curve calculation for the plasma SIV RNA levels between 
wk 1 and 20 following infection (Figure 3C, Table 2).  
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Figure 3. Correlation between vaccine-induced immune responses and plasma viral load 
in the vaccine group. Correlation matrices were generated using Spearman nonparametric 
correlation to compute the correlation coefficient for each pair of variables including 
plasma antibody and Elispot responses to number of PCS peptides and plasma SIV RNA 
levels in the vaccine group. The plasma SIV RNA levels were assessed on 2-4 weeks and 
9-14 weeks following SIV challenge, representing peak (A) and viral set point (B) viral 
load, respectively. Area-under-the curve calculations (C) for the plasma SIV RNA levels 
were also assessed in these monkeys.  
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 Peak Set-point AUC 
 
1Rho (ρ) 2P value 1Rho (ρ) 2P value 1Rho (ρ) 2P value 
Plasma antibody to 
No. Of PCS peptides -0.63 0.03 -0.02 0.94 -0.63 0.03 
Elispot response to 
No. Of PCS peptides 0.30 0.37 0.03 0.92 0.06 0.84 
Total -0.41 0.19 -0.14 0.67 -0.56 0.06 
 
Table 2. Correlation between vaccine-induced immune responses and plasma viral load 
in the vaccine group 1 The Spearman correlation coefficients (ρ) are shown. 
2 Exact P values for nonparametric Spearman correlation are shown. 
 
Amino acid mutations in sequences around the PCS sites and correlations with viral 
load 
As shown in Figure 4, twelve protease cleavage sites are located across the HIV-
1 genome. Five cleavage sites are found on the Pr55Gag protein, six cleavage sites are 
found on the Gag-Pol protein, and one cleavage site is found on the Nef protein. 
Viral sequence analysis revealed extensive mutations around PCS regions (Figure 5) in 
both vaccinated monkeys and control monkeys over 20 wks after infection.  
 
  
	  29 
 
 
Figure 4.  A schematic illustrating landmarks of SIVmac239 genome and 12 proteolytic 
cleavage sites. Twelve unique cleavage sites between Gag, Gag-Pol and Nef precursor 
polyproteins are designated. 
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B 
 
Figure 5. The major PCS amino acid mutations of plasma SIVmac239 in a cohort of 
monkeys. The frequencies of each PCS amino acid mutation following infection with 
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SIVmac239 in the vaccine  (A) and control (B) groups are shown in various colored lines 
and corresponding plasma SIV RNA copies are shown in black solid line. 
 
 Comparisons of the PCS mutation frequencies were conducted at each time point 
between the vaccine and control groups. The virus recovered from several vaccinated 
animals showed increased mutation frequencies in either PCS2 or PCS12 region. 
Specifically, virus recovered from the vaccine group showed significantly higher 
frequencies of mutation in PCS12 region (P=0.009) compared to the mutation 
frequencies in the control group (Figure 6). Amino acid mutation in PCS2 (-8) was 
associated with moderate yet significant increase of viral replication. However, amino 
acid mutation in PCS12 (-8) displayed a negative correlation with the plasma viral load 
(see Figure 7 below).  
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-8 -7 -6 -8 -7 -6 -5 4 5 6 7 9 
PèR GèD GèE/R GèR/E QèR/L YèC MèV/T AèT EèK EèK/R RèG KèR/E 
 
         
 
Figure 6. Comparison of the major PCS amino acid mutation frequencies between the 
vaccine and control groups. Total sum of frequencies found in the major PCS were 
compared. The comparison of the values from the groups of animals was determined 
using a non-parametric one-way ANOVA Kruskal-Wallis test with Dunn's multiple 
comparison test or the Mann-Whitney test.  The amino acid mutations less than 10% in 
other PCS sites are not included in the analysis. 
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Figure 7. Correlation between the major PCS amino acid mutation and changes in 
plasma viral load in the vaccine group. Correlation matrices were generated using 
Spearman nonparametric correlation to compute the correlation coefficient for each pair 
of variables including PCS amino acid mutations (PCS2: -8, -7, and -6 and PCS12: -8) 
and plasma SIV RNA levels in the vaccine group. 
 
Construction of major PCS amino acid mutation. 
 In order to assess the effects of the PCS vaccine on SIV fitness and evolution, SIV 
was routinely isolated from blood samples drawn from Cynomolgus macaques used in the 
study. Analysis of the isolated SIV sequences from the monkeys during the periods when 
they experienced peak (ranging from weeks 2-4 post-infection) and set point (ranging 
from weeks 6-17 post-infection) viral loads led to the selection of 5 mutations which 
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persisted throughout the study in the majority of the subjects. Three of these mutations 
(PCS2-8, PCS2-7 and PCS2-6) occurred on PCS2, which lies on the sequence for the Gag 
capsid protein, p27, while the two other mutations (PCS12-8(E/R)) occurred on PCS12, 
which is on the sequence for the Nef regulatory protein. To introduce point mutations 
into each PCS region, the fragment between the BamHI and SphI sites, and the SphI and 
XhoI was subcloned into the pSP73 vector to generate a clone termed pSP73-PCS2, and 
the fragment between the SphI and XhoI sites was subcloned into the pSP73 vector to 
generate the clone termed pSP73-PCS12 (Figure 8A). The complete list of mutations 
inserted in to the full length SIVmac239 genome is shown in Table 3. 
 
 PCS2 PCS12 
 -8 -7 -6 -8 
SIVmac239-WT P G Q G 
SIVmac239-PCS2(-8) R G Q G 
SIVmac239-PCS2(-7) P D Q G 
SIVmac239-PCS2(-6) P G E G 
SIVmac239-PCS12(-8R) P G Q R 
SIVmac239-PCS12(-8E) P G Q E 
SIVmac239-PCS2(-8)/PCS12(-8R) R G Q R 
SIVmac239-PCS2(-7)/PCS12(-8R) P D Q R 
SIVmac239-PCS2(-6)/PCS12(-8R) P G E R 
SIVmac239-PCS2(-8)/PCS12(-8E) R G Q E 
SIVmac239-PCS2(-7)/PCS12(-8E) P D Q E 
SIVmac239-PCS2(-6)/PCS12(-8E) P G E E 
 
Table 3. Positional mutations induced by site-directed mutagenesis at each respective 
PCS site. Amino acid (AA) substitutions for each of the PCS mutations that were 
constructed are shown in red. 
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 The QuikChange site-directed mutagensis kit (Stratagene, La Jolla, Calif.) was 
used to introduce PCS2 (-8, -7 and -6) and PCS12 (-8) point mutations procedures 
described by manufacturer (Figure 8B). The presence of all point mutations was 
confirmed by direct sequencing (Figure 8C). The BamHI-SphI fragment was cloned 
back into SIVmac239 to generate the SIVmac239-PCS2 mutant clones; the SphI-XhoI 
fragment was cloned into the SIVmac239 to generate both SIVmac239-PCS12 (-8R) and 
SIVmac239-PCS12 (-8E) clones (Figure 8D). 
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Figure 8. Construction of major PCS amino acid mutations. (A) Digestion of both 
SIVmac239 and pSP73 vector with BamHI and SphI or SphI and XhoI followed by 
ligation using T4 DNA ligase to create pSP73-PCS2 and pSP73-PCS12, respectively. (B) 
Site-directed mutagenesis strategy to create the point mutations. (C) Sequencing 
alignments to confirm the successful introduction of each individual mutant into the 5 
SIVmac239. A) PCS2-8, B) PCS2-7, C) PCS2-6, D) PCS12-8E, E) PCS12-8R. (D) Full 
length SIVmac239 PCS mutant clones. 
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 Once all the mutations were confirmed correct in the new full length mutant virus, 
we produced infectious virus stocks by transient transfection of 293T cells with SIVmac239 
wild type or each PCS mutant plasmid using Lipofectamine 2000 (Invitrogen, Carlsbad, 
CA) according to the manufacturer's instructions. All 293 T cells were transfected at 85% 
confluence, virus-containing supernatant were collected 48 hrs. after transfection.  The 
supernatants were clarified centrifugation and then frozen at -80C for titration and virus 
RNA level quantitation.  These stocks are being titrated by TCID50 analysis for use in 
competitive fitness evaluations. 
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FUTURE WORK 
Competitive Fitness Assay- 
 To continue the evaluation of the PCS vaccine on SIVmac239 fitness, competitive 
fitness assays will be carried out as described by Anastassopoulou et al. 
(Anastassopoulou et al., 2007). However, we have adapted the described HIV-specific 
assay for use with SIV isolates.  In selecting the appropriate assay for viral fitness 
determinations, there were a number of limitations and concerns. A few of these 
experimental decisions are shown below (Figure 9). For example, using conventional RT 
or p24 antigen capture assays to distinguish two similar SIV isolates in a single culture is 
not currently feasible (Quiñones-Mateu et al., 2000). 
 
 
Figure 9. Practical considerations in the design of a competitive viral fitness assay.  
Schematic representation of each of 5 aspects to be considered in the selection of the 
most appropriate assay conditions including Culture environment 1, Virus isolate 2, 
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Inoculum titration 3, Assay specifics 4, and Experimental endpoints 5. Adapted from 
Quinones-Mateau and Arts, 2006.    
 
 However, it is possible to make this distinction using a comparator virus that 
contains a unique region that can be used to differentiate itself from other virus isolates. 
In order to provide a more accurate portrayal of in vivo viral fitness a competitive fitness 
assay using mutant SIVmac239 and wild type SIVmac239, which represents the founder 
virus, was developed based on the assay used by Anastassopoulou et al. 
(Anastassopoulou et al., 2007). In this assay real time TaqMan quantitative PCR (QPCR) 
is used to quantify competing viruses using probes that differentially target silent 
mutations artificially created on the vif gene. Our assay will consist of a wild type 
SIVmac239 containing silent mutations to be our comparator virus versus the 
SIVmac239 clones containing mutations in inserted in to the PCS2 and PCS12 fragments 
by site-direct mutagenesis. 
 
Figure 10. General setup of a virus competition assay.   
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Fitness (W) can be calculated by the proportion of virus in a dual infection (fo) divided by 
its initial level in the inoculum (io). The relative fitness difference (Wdiff) can be 
determined by the ratio of the more fit (Wm) and less fit (WL) virus.  Figure adapted from 
Quinones-Mateau and Arts, 2003. 
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DISCUSSION 
 	   This study was initiated to examine the effectiveness of a novel vaccine strategy 
targeting viral PCS. The three main goals of this study are first to identify prominent 
amino acid mutations around PCS region that were thought to be associated with 
selective pressure elicited by an experimental vaccine, secondly to create SIVmac239 
clones containing PCS mutations selected by immune pressure and finally to assess the 
comparative fitness of these mutant clones to a wild type SIVmac239, which would 
represent a founder virus. 
  
Vaccines Targeting Protease Cleavage Sites 
 HIV-1 is an incredibly dynamic virus that uses a high mutation rate and rapid 
replication cycle to effectively escape host immune responses (Barouch, 2013; Coffin, 
1995). Coupled with the ability to integrate into a host cell genome and become latent, 
rendering the virus invisible to the immune system, HIV-1 has demonstrated that 
conventional vaccine concepts may not be capable of preventing infection and 
eradicating active infection. Most of the previously described vaccine attempts are 
examples of conventional concepts that try to stimulate broad, potent antibody responses 
to known HIV-1 antigens, such as Gag, Pol and Nef peptides. However, the classical 
vaccine approach to elicit either T cell or antibody responses against HIV-1 has failed so 
far or produced a modest effect. Therefore, new approaches and ideas are needed to 
develop novel and effective vaccines. 
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 The PCS targeting vaccine being evaluated varies from previous vaccine attempts 
by looking into the natural immunity seen in ECs and LTNPs for insights into fighting 
the virus. Several studies have revealed that a key difference between LTNPs and HIV+ 
individuals who progress to AIDS involves the degree of immune activation and 
specificity of immune response (Alimonti et al., 2006; Fowke et al., 1996; Mogensen et 
al., 2010; Zaunders & van Bockel, 2013). Instead of relying on antibody-mediated 
humoral immunity, many LTNPs possess specific HLA alleles corresponding to specific 
peptide epitopes that appear to effectively control HIV pathogenesis via cell-mediated 
processes. The degree of system wide immune activation is also believed to play a pivotal 
role in the progression to AIDS (Mogensen et al., 2010).Chronic immune activation is 
thought to cause “exhaustion” of the immune system, lessening its effectiveness, while 
simultaneously providing more targets for HIV infection through the systemic 
proliferation response caused by chronic immune activation. 
 This PCS vaccine differs by targeting very specific, highly conserved PCS that 
are known to have immunogenic effects mediated by many prevalent HLA class I alleles. 
By generating a specific, focused immune response this vaccine could potentially avoid 
the detrimental side effect of “over immune activation”. In addition, the vaccine could 
also force the mutation of conserved sites that are essential for viral replication, rendering 
the virus less fit and pathogenic. Viral fitness has been shown to be a critical factor in 
determining viral set point and rebound, therefore, any therapy capable of forcing the 
mutation of less fit virus would be worth exploring (Trkola et al., 2003). 
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 Continuing the on-going characterization of viral fitness in the context of vaccine-
elicited immune pressure is critical for designing an effective vaccine concept to combat 
HIV-1. Competitive fitness assays allow researchers to more accurately measure the 
effectiveness of vaccines by creating an environment that is more similar to the in vivo 
environment in an active infection. Although there will always be limitations to the value 
of ex vivo assays compared to in vivo mimicking the intra-species competition that exist 
from in vivo viral swarms is a step in the right direction. 
  In addition to the mutants we created, harboring single mutations, we plan to 
create mutant viruses harboring the various combinations of mutations possible. This will 
assess whether multiple PCS mutations have a multiplicative effect on fitness and 
infectivity of virus. We also plan to further describe the molecular characteristics of these 
mutant viruses using ELISA and Western Blotting techniques.  
 With all of the encouraging results and the knowledge gained from this pilot 
study, we will be able to provide pivotal information to develop an effective HIV vaccine 
that selectively target the key sites of HIV-1 such as PCS and prevent from HIV-1 
acquisition.  
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